ReviewImmunotherapy2009
Separating graft-versus-leukemia from graft-versus-host disease in allogeneic hematopoietic stem cell transplantation.
Review in Immunotherapy, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 68 citations in OpenAlex.
- A multicentre UK study of GVHD following DLI: rates of GVHD are high but mortality from GVHD is infrequent.Bone marrow transplantation · 2015Trial
- Review
- Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Allogeneic stem cell transplantation in the treatment of acute myeloid leukemia: An overview of obstacles and opportunities.World journal of clinical cases · 2023Review
- The role of AMP-activated protein kinase in GVHD-causing T cells.Immunometabolism (Cobham, Surrey) · 2022Review
- Predicting the risk of acute kidney injury after hematopoietic stem cell transplantation: development of a new predictive nomogram.Scientific reports · 2022Article
- Glucose oxidase induces mobilization of long-term repopulating hematopoietic cells in mice.Stem cells translational medicine · 2021Article
- Deletion of AMPK minimizes graft-versus-host disease through an early impact on effector donor T cells.JCI insight · 2021Article
- Predictors of hematologic malignancy relapse in patients with advanced chronic graft-versus-host disease.Bone marrow transplantation · 2021Article
- Article
- Effective Immunosurveillance After Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.Cancer management and research · 2021Review
- Independent risk factors and long-term outcomes for acute kidney injury in pediatric patients undergoing hematopoietic stem cell transplantation: a retrospective cohort study.BMC nephrology · 2020Observational
- Targeting Histone Deacetylases to Modulate Graft-Versus-Host Disease and Graft-Versus-Leukemia.International journal of molecular sciences · 2020Review
- Regulation of the Immune Balance During Allogeneic Hematopoietic Stem Cell Transplantation by Vitamin D.Frontiers in immunology · 2019Review
- Mini-review of kidney disease following hematopoietic stem cell transplant .Clinical nephrology · 2018Review
- Article
- Peripheral Blood Stem Cell Mobilization in Healthy Donors by Granulocyte Colony-Stimulating Factor Causes Preferential Mobilization of Lymphocyte Subsets.Frontiers in immunology · 2018Article
- Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia and the Role of MRD: A Single Centre Experience from India.Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion · 2018Article
- Modulation of Immune Checkpoints and Graft-versus-Leukemia in Allogeneic Transplants by Antagonizing Vasoactive Intestinal Peptide Signaling.Cancer research · 2016Article
- Single-Agent Post-Transplantation Cyclophosphamide as Graft-versus-Host Disease Prophylaxis after Human Leukocyte Antigen-Matched Related Bone Marrow Transplantation for Pediatric and Young Adult Patients with Hematologic Malignancies.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Routine methods to maximize the graft-versus-leukemia (GvL) activity of allogeneic hematopoietic stem cell transplantation (HSCT) without the detrimental effects of graft-versus-host disease (GvHD) are lacking. Depletion or inhibition of alloreactive T cells is partially effective in preventing GvHD, but usually leads to decreased GvL activity. The current model for the pathophysiology of acute GvHD describes a series of immune pathways that lead to activation of donor T cells and inflammatory cytokines responsible for tissue damage in acute GvHD. This model does not account for how allotransplant can lead to GvL effects without GvHD, or how the initial activation of donor immune cells may lead to counter-regulatory effects that limit GvHD. In this review, we will summarize new findings that support a more complex model for the initiation of GvHD and GvL activities in allogeneic HSCT, and discuss the potential of novel strategies to enhance GvL activity of the transplant.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.